Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP8471] to cAMP
- Suitable for: ELISA, ICC/IF
- Reacts with: Species independent
Product nameAnti-cAMP antibody [EP8471]
See all cAMP primary antibodies
DescriptionRabbit monoclonal [EP8471] to cAMP
SpecificityThis antibody does not cross react with cGMP, GMP, GDP, cIMP, cCMP, or adenosine.
Tested applicationsSuitable for: ELISA, ICC/IFmore details
Species reactivityReacts with: Species independent
Chemical/ Small Molecule corresponding to cAMP conjugated to keyhole limpet haemocyanin.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab134901 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use a concentration of 0.1 µg/ml.|
|ICC/IF||Use a concentration of 5 µg/ml.|
RelevanceCyclic adenosine monophosphate (cAMP) plays a key role as an intracellular second messenger for transduction events that follow a number of extracellular signals. The G-Protein Coupled Receptors (GPCR) is the largest family of cell surface receptors. They can be activated by different ligands, such as neurotransmitters, hormones, ions, small molecules, peptides, and other physiological signaling molecules. Typically, the binding of the ligands to its receptor resulting in the activation of G-proteins, in return, activates the effector adenylyl cyclase evoking the production of cAMP. The activation of a protein kinase by cAMP results in the phosphorylation of substrate proteins. Currently successful drugs in marketing have been developed to target these receptors. Among the GPCRs, ~367 receptors are potential drug development targets, but only about 20 have been used to generate therapeutically and commercially successful drugs so far. Because the involvement of cAMP can amplify the response of the ligand binding, the second messenger cAMP has been largely employed to monitor the activation of the GPCR to facilitate the therapeutic drug discovery.
- 3' 5' cyclic adenosine monophosphate antibody
- Cyclic adenosine monophosphate antibody
- Cyclic AMP antibody
Competitive inhibition ELISA using ab134901. 50µl of cAMP-SPDP-BSA was coated in 96-wells. After 1% BSA blocking, 25 µl cAMP, AMP, ADP, ATP, cGMP, GMP, GDP, GTP, cIMP, cCMP, Adenosine, H2O and 25 µl of ab134901 were added. HRP conjugated goat anti-rabbit IgG-Fc-HR antibody was used to develop the color.
Competitive ELISA assay using ab134901. 50 µl cAMP-SPDP-BSA was coated in 96-wells. After 1% BSA blocking, serial dilution of ab134901, 25 µl of cAMP, and H2O (negative control) were added. HRP conjugated goat anti-rabbit IgG-Fc antibody was used to develop the color.
ab134901 staining cAMP in SK-N-SH cells treated with (R)-(+)-Methanandamide (ethanol solution) (ab120361), by ICC/IF. Increase in cAMP expression correlates with increased concentration of (R)-(+)-Methanandamide (ethanol solution), as described in literature.
The cells were incubated at 37°C for 10 minutes in media containing different concentrations of ab120361 ((R)-(+)-Methanandamide (ethanol solution)) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab134901 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
ab134901 has been referenced in 1 publication.
- Jiang X et al. Pinoresinol promotes MC3T3-E1 cell proliferation and differentiation via the cyclic AMP/protein kinase A signaling pathway. Mol Med Rep 20:2143-2150 (2019). PubMed: 31322181